Back to top

Analyst Blog

UCB (UCBJF) recently presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia. The data was presented at the European League Against Rheumatism (EULAR) Congress.

According to the recent findings, active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA) patients treated with Cimzia showed improvements in pain, fatigue and health-related quality of life. Cimzia-treated PsA and axSpA patients have shown better workplace and household productivity, as well as more participation in social and daily activities as compared to those being administered placebo.

Similar observations were seen in ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) patients treated with Cimzia.

Cimzia is currently approved for Crohn’s disease and rheumatoid arthritis. Cimzia sales increased 27% year over year in the first quarter of 2013.

In Feb 2013, UCB filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for two additional indications – PsA and axSpA. These regulatory filings were based on the phase III RAPID-PsA and RAPID-axSpA studies.

RAPID-PsA was a double-blind, placebo-controlled, phase III study which showed improvements in the signs and symptoms of PsA compared to placebo in adult patients with or without prior anti-TNF (tumor necrosis factor) exposure.

RAPID-axSpA was a randomized, double-blind, placebo-controlled, phase III study which showed that both dosing regimens of Cimzia reduced the signs and symptoms of axSpA as compared to placebo.

Currently, the psoriatic arthritis market has drugs like AbbVie Inc.’s (ABBV - Analyst Report) Humira and Johnson & Johnson’s (JNJ - Analyst Report) Simponi among others.

UCB carries a Zacks Rank #3 (Hold). However, Santarus, Inc. looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 114.66 +6.14%
LANNETT COM… LCI 40.60 +3.26%
ERBA DIAGNO… ERB 3.87 +1.84%
CANADIAN SO… CSIQ 35.58 +1.72%
US SILICA H… SLCA 69.00 +1.47%